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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Several studies have shown the renoprotective effects of pentoxifylline
in the treatment of chronic kidney disease (CKD). This study was conducted to examine
whether there was an increased benefit of including pentoxifylline with angiotensin-
converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) in the treatment
of CKD.
Methods: A single-center retrospective analysis was conducted. A total of 661 Stage 3B-5 CKD
patients who received ACEI or ARB treatment were recruited. The patients were divided into
the pentoxifylline use group and the no pentoxifylline group. Renal survival analysis of the two
groups was compared. Subgroup analysis was performed by dividing the patients into lower [ur-
ine protein to creatinine ratio (UPCR)< 1 g/g] and higher (UPCR 1 g/g) proteinuria sub-
groups.
Results: There was no between-groups difference regarding mortality and cardiovascular
events. Addition of pentoxifylline showed a better renal outcome (p Z 0.03). The protective
effect of add-on pentoxifylline was demonstrated in the higher proteinuria subgroup
(pZ 0.005). In the multivariate Cox regression model, pentoxifylline use also showed a better
renal outcome [hazard ratio (HR): 0.705; 95% confidence interval (CI): 0.498e0.997;
p Z 0.048]. This effect was more prominent in the higher proteinuria subgroup (HR: 0.602;
95% CI: 0.413e0.877; p Z 0.008).ave no conflicts of interest relevant to this article.
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220 P.-M. Chen et al.Conclusion: In the advanced stages of CKD, patients treated with a combination of pentoxifyl-
line and ACEI or ARB had a better renal outcome than those treated with ACEI or ARB alone.
This effect was more prominent in the higher proteinuria subgroup. More large randomized
control trials are needed to provide concrete evidence of the add-on effect of pentoxifylline.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Chronic kidney disease (CKD) is an important disease that
threatens the integrity of human health and society. In
Taiwan, the incidence of end-stage renal disease (ESRD) is
very high. The causes of ESRD are diabetes mellitus (DM)
nephropathy, glomerulonephritis, and herb neph-
ropathy.1e3 Understanding the pathogenesis of CKD and
developing an effective treatment to stop or slow down the
progression of CKD to ESRD is an important issue. Many
treatment strategies or targets for CKD were submitted,
such as erythropoietin, microRNA, multidisciplinary edu-
cation, pericyte manipulation.4e8 However, these strate-
gies are still under investigation in animal studies or are yet
to be extensively evaluated in practice.
Angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin II receptor blockers (ARBs) were the hallmarks
of CKD treatment in the last few decades. They have been
shown to slow down the progression of CKD and decrease
proteinuria in patients with diabetic nephropathy9e12 and
nondiabetic renal disease.13 In addition to the beneficial
effects in the early stages of CKD, their protective role in
advanced stages of CKD was also demonstrated in ran-
domized control trials.14,15 However, most patients still
eventually progress to ESRD even after intensive treatment
with ACEI or ARB. Therefore, finding a new treatment
method or combining another agent with ACEI or ARB to
further slow down the progression of CKD is very important.
Pentoxifylline, a phosphodiesterase inhibitor, was shown
to inhibit renal inflammation, fibrosis, and renal function
progression in several animal studies.16e20 In humans,
pentoxifylline also shows an anti-inflammatory effect by
decreasing serum tumor necrosis factor-a (TNF-a)21 and
urinary monocyte chemoattractant protein-1 (MCP-1)
levels.22 There were also studies showing its capacity to
decrease proteinuria in cases with diabetic nephropa-
thy.23,24 The antiproteinuric effect was also shown in
nondiabetic kidney disease.25,26 However, only limited ev-
idence is available regarding its effect on slowing down
renal function deterioration. Our previous clinical study
showed that pentoxifylline combined with losartan signifi-
cantly decreased proteinuria as well as a trend toward
slower decline of renal function progression in patients with
CKD Stages 3e5.27 Perkins et al. also demonstrated the
beneficial effect of add-on pentoxifylline in hypertensive,
proteinuric patients with advanced stages of CKD and
rapidly declining estimated glomerular filtration rate
(eGFR) in a double-blind controlled trial.28 The two studies
were limited by the small sample size. Before conducting a
larger scale of randomized control trial, we performed a
retrospective analysis of the use of pentoxifylline at our
medical center to provide more evidence for the universal
use of pentoxifylline on CKD patients.Patients and methods
Participants
A single-center retrospective study was conducted in Na-
tional TaiwanUniversity Hospital. Participantswho attended
the pre-ESRD program in our hospital were recruited. The
pre-ESRD program was a multidisciplinary program, which
integrated the care of nephrologists, nursing staff, dietician,
and pharmacists for patients with advanced stages of CKD.
The study included patients between 18 and 80 years of age
with eGFR< 45 mL/minute/1.73 m2 and patients in the pre-
ESRD program for at least 3 months between 2007 and 2011.
The eGFRs were calculated using the simple Modification of
Diet in Renal Disease (MDRD) equationdeGFR (mL/minute/
1.73 m2)Z 186 Scr1.154 age0.203 0.742 (if female)
1.212. By reviewing the medical record, patients who
received ACEI or ARB treatment were included in this anal-
ysis. This study was approved by the National Taiwan Uni-
versity Hospital Research Ethics Committee.
Data collection
Age, body mass index, sex, smoking status, and alcohol
intake were ascertained by a questionnaire while enrolling
the patient for the pre-ESRD program. Data on underlying
comorbidities such as DM, hypertension, and cardiovascular
diseases were also collected. The blood pressure (BP) levels
at the time of enrolment to the pre-ESRD program were
recorded. The cutoff value of hypertension was defined as
either systolic BP 130 mmHg or diastolic BP 80 mmHg.
Biochemical laboratory data including serum creatinine,
albumin, calcium, phosphate, cholesterol, triglyceride,
hemoglobin, and urine protein to creatinine ratio (UPCR)
were collected. The use of pentoxifylline was defined by
the medical record during enrolment, regardless of dosage.
The duration of ACEI/ARB and pentoxifylline treatment
during the follow-up period was recorded.
Outcomes
The primary outcome of the study was the initiation of
renal replacement therapy (RRT) including hemodialysis,
peritoneal dialysis, and renal transplantation. The timing of
initiation of RRT was determined by nephrologists individ-
ually. The secondary outcome was death. The outcomes of
all patients were observed until December 31, 2012.
Statistical analysis
Baseline characteristics were described as mean standard
deviation for continuous variables, and frequency for
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between those with or without pentoxifylline use were
analyzed using the t test. Differences in categorical vari-
ables were compared using the Chi-square test. The UPCR
was skewed to right, and expressed as median (25th and
75th quartile). The UPCR was compared by ManneWhitney
U test between groups, and Wilcoxon signed-rank test was
applied to evaluate the effect of pentoxifylline on the
change of UPCR after 1 year of follow up.
Person-years of each participant were calculated from
the date of entry to the date of initiation of RRT, death, or
December 31, 2012. The risk of initiation of RRT between
groups with or without pentoxifylline use was estimated by
KaplaneMeier method and the statistical significance of the
difference was examined by log-rank test. We used Cox
regression model to examine the association between
pentoxifylline use and development of ESRD necessitating
RRT. Multivariable models were adjusted for age, sex, BP,
eGFR, history of DM, and UPCR. The UPCR was dichoto-
mized. Hazard ratios (HRs) and 95% confidence intervals
(CIs) were generated to evaluate the association between
pentoxifylline use and development of ESRD.
All statistical tests were two-tailed, and p< 0.05 was
considered to indicate statistical significance. The statisti-
cal analyses were performed with the use of SPSS version 19
and STATA version 12.Results
Baseline characteristics
A total of 661 patients were included in this study. The
median follow-up period was 2.25 years. The most common
etiologies of CKD were DM (50.7%), glomerular diseaseTable 1 Baseline characteristics between participants with or
No pentoxifylline use (n Z
Age 62.83  12.44
Sex (male) 57.4%
BMI (kg/m2) 25.58  4.50
eGFR (mL/minute/1.73 m2) 25.34  10.99
DM 44.6%
BP  130/80 mmHg 75.6%
SBP (mmHg) 134.81  16.27
DBP (mmHg) 76.76  10.42
Hemoglobin (g/dL) 11.43  2.15
Albumin (g/dL) 4.37  0.41
Ca (mmol/L) 2.28  0.15
P (mg/dL) 3.94  0.87
Uric acid (mg/dL) 8.10  1.74
Cholesterol (mg/dL) 193.85  41.49
Triglyceride (mg/dL) 177.03  114.75
UPCR (g/g) 1.102 (0.371e2.475)
UPCR  1g/g 53.7%
Continuous variables were compared using the t test and categorical
BMI Z body mass index; BP Z blood pressure; Ca Z serum calcium
eGFR Z estimated glomerular filtration rate; P Z serum phosphate
creatinine ratio.(27.8%), and hypertension (7.3%). Among them, 419 pa-
tients used both pentoxifylline and ACEI or ARB and 242
patients used ACEI or ARB only. After comparing the base-
line characteristics between participants with or without
pentoxifylline use, we found no differences for age, sex,
baseline eGFR, percentage of high BP, body mass index,
hemoglobin, calcium, phosphate, albumin, cholesterol,
uric acid, and baseline UPCR (Table 1). Most of the partic-
ipants with pentoxifylline use had more DM than those
without pentoxifylline use. All patients received a standard
dosage of ACEI or ARB. Nearly no dosage change was
documented while prescribing them. During the follow-up
period, the use of ACEI or ARB was ceased in 41.1% of pa-
tients in the pentoxifylline group and in 39.3% in the no
pentoxifylline group due to progressive deterioration of
renal function or hyperkalemia in the later stage. There
was no statistical difference between groups regarding the
percentage of medication cessation (p Z 0.651). The
overall medication time of ACEI or ARB during the study
period was 77.3% in the pentoxifylline use group, and 81.3%
in the no pentoxifylline group, without a statistically sig-
nificant difference. The use of pentoxifylline was docu-
mented in 84.5% of the follow-up time in the pentoxifylline
group. Almost all patients remained on the same dose of
pentoxifylline. The dosage of pentoxifylline prescribed was
400e800 mg/day, according to different eGFR. Most pa-
tients (Stages 4e5) received a pentoxifylline dose of 400 mg
q.d. Patients in Stage 3B received 800 mg q.d. No significant
side effect of pentoxifylline was reported in the document.
There were 517 patients having both baseline and 1-year
follow-up UPCR data in the analysis. There was no change in
UPCR change in both groups after 1 year of follow up. The
difference of UPCR change in 1 year seemed smaller in the
pentoxifylline group than in the no pentoxifylline group;
however, it did not reach statistical significance (Table 2).without use of pentoxifylline.
242) Pentoxifylline use (n Z 419) p
62.63  12.61 0.84
63.2% 0.14
25.62  4.47 0.92
26.60  9.74 0.14
54.2% 0.02
71.1% 0.21
133.18  18.63 0.26
75.47  10.96 0.14
11.39  2.18 0.83
4.35  0.43 0.52
2.27  0.15 0.47
3.85  0.72 0.17
8.21  2.03 0.48
193.47  47.54 0.92
169.45  111.53 0.43
1.112 (0.439e2.667) 0.51
54.7% 0.82
variables were compared using the Chi-square test.
level; DBP Z diastolic blood pressure; DM Z diabetes mellitus;
level; SBP Z systolic blood pressure; UPCR Z urine protein to
Table 2 Difference of urine protein to creatinine ratio in 1 year between pentoxifylline versus no pentoxifylline use.
Overall No pentoxifylline use (n Z 179) Pentoxifylline use (n Z 338) p
Baseline Difference Baseline Difference
UPCR (g/g) 0.973 (0.344e2.035) 0.004 (0.436e0.425) 1.097 (0.441e2.453) 0.033 (0.531e0.374) 0.34
UPCR Z urine protein to creatinine ratio.
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RRT was applied to 81 patients (19.3%) in the pentoxifyl-
line group, including 54 patients receiving hemodialysis,
23 patients receiving peritoneal dialysis, and four
receiving renal transplantation, and there were 61 pa-
tients (25.2%) in the no pentoxifylline group, including 45
hemodialysis and 16 peritoneal dialysis cases. There were
no differences in eGFR upon initiating RRT in the pen-
toxifylline group and the no pentoxifylline use group (3.76
vs. 3.94 mL/minute/1.73 m2; p Z 0.40). A KaplaneMeier
curve for the effect of pentoxifylline on renal survival is
shown in Fig. 1. Participants using pentoxifylline had a
better renal outcome when compared with those without
pentoxifylline use (p Z 0.03). In the Cox regression
model, pentoxifylline use has a protective effect on
developing ESRD with crude HR of 0.694 (95% CI:
0.498e0.968; p Z 0.03). After multivariate adjustment,
participants with pentoxifylline use have 29.5% lower risk
of developing ESRD necessitating RRT compared with
those without pentoxifylline use (HR: 0.705; 95% CI:
0.498e0.997; p Z 0.048; Table 3).
During the follow-up period, the mortality rate was 5.3%
and 4.1% in the pentoxifylline group and the no pentox-
ifylline group, respectively. There were no between-groups
differences regarding the overall mortality (p Z 0.74), or
cardiovascular death (p Z 0.23).Figure 1 KaplaneMeier curve of the proportion of free from
renal replacement therapy between groups with and without
pentoxifylline use. Patients treated with a combination of pen-
toxifylline and ACEI or ARB had better renal outcome than those
treated with ACEI or ARB alone. ACEI Z angiotensin-converting
enzyme inhibitor; ARB Z angiotensin II receptor blocker.Subgroup analysis
Because proteinuria is a strong risk factor of developing
ESRD, we further divided these patients into low
(UPCR< 1 g/g; n Z 302) and high (UPCR 1 g/g; n Z 359)
proteinuria subgroups. A KaplaneMeier curve for the effect
of pentoxifylline on developing ESRD in each proteinuria
subgroup is shown in Fig. 2. The beneficial effect of pen-
toxifylline on renal outcome was seen in the high protein-
uria subgroup (p Z 0.005), but not in the low proteinuria
group (pZ 0.33). In the multivariate Cox regression model,
participants with pentoxifylline use have 39.8% lower risk of
developing ESRD necessitating RRT (HR: 0.602; 95% CI:
0.413e0.877, p Z 0.008) in the high proteinuria group.
However, there was no significant effect of pentoxifylline in
the low proteinuria group (Table 4).
Discussion
In this study we have demonstrated that in patients with
moderate to severe CKD with higher proteinuria, a combi-
national treatment of pentoxifylline and ACEI or ARB pro-
vided 39.8% lower risk of developing ESRD than treatment
with ACEI or ARB alone. There are also several small-scale
randomized control trials showing that there was an addi-
tive renoprotective effect of pentoxifylline when combined
with ACEI/ARB in moderate to advanced CKD21,28 or DM
nephropathy patients.29 Lin et al. found that there was a
tendency of slower renal function progression in the pen-
toxifylline treatment group,27 while in the study by Navarro
et al the renal function was stable in both groups.30 How-
ever, in the early stages of CKD, none of the previous
studies showed any effect of pentoxifylline on creatinine
clearance.25,31e33 This is not surprising because the study
period is short and all the studies are small scale. There-
fore, it is very difficult to obtain any conclusion from the
results of previous studies. Our study included a total of 661
CKD patients in the moderate to advanced stages. This is
the largest one to date. The follow-up period was up to 5
years. Thus, it is easier to see the difference of renal
function change. Interestingly, by dividing the patients into
lower and higher proteinuria subgroups, we demonstrated
that the renoprotective effect was more prominent in the
higher proteinuria subgroup, but not in the lower protein-
uria subgroup. Perkins et al demonstrated the effect of
add-on pentoxifylline in slowing down GFR decrease in hy-
pertensive and proteinuric patients with advanced stages of
CKD and rapidly declining eGFR, indicating benefits similar
to this study.28 Addition of pentoxifylline to standard care
with ACEI or ARB was proved to be beneficial in further
decreasing proteinuria in both diabetic nephropathy32,34
and nondiabetic patients.26,35 However, our study only
Table 3 Crude and multivariate adjusted hazard ratio of the risk of developing ESRD requiring RRT.
Crude HR (95% CI) p Adjusted HR (95% CI) p
Pentoxifylline 0.694 (0.498e0.968) 0.031 0.705 (0.498e0.997) 0.048
Age
18e55 y 1.000 d 1.000 d
56e64 y 0.678 (0.447e1.030) 0.07 0.659 (0.424e1.026) 0.07
65e73 y 0.488 (0.307e0.774) 0.002 0.603 (0.368e0.989) 0.045
74e80 y 0.407 (0.250e0.661) <0.001 0.602 (0.358e1.012) 0.06
Sex (male) 0.938 (0.668e1.317) 0.71 1.843 (1.292e2.629) 0.001
eGFR (mL/minute/1.73 m2) 0.87 (0.85e0.89) <0.001 0.880 (0.859e0.902) <0.001
DM 1.069 (0.769e1.486) 0.69 1.078 (0.731e1.590) 0.70
BP  130/80 mmHg 2.079 (1.348e3.205) 0.001 1.050 (0.670e1.646) 0.83
Log UPCR (g/g) 6.72 (4.74e9.53) <0.001 6.609 (4.086e10.690) <0.001
Reference group age: 18e55 years.
BPZ blood pressure; CIZ confidence interval; DMZ diabetes mellitus; eGFRZ estimated glomerular filtration rate; ESRDZ end-stage
renal disease; HR Z hazard ratio; RRT Z renal replacement therapy; UPCR Z urine protein to creatinine ratio.
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might be due to the higher variation about the degree of
proteinuria in our patients masking the effect of pentox-
ifylline in statistical process.
The mechanism of add-on effect of pentoxifylline might
be explained by several studies revealing the effect of
pentoxifylline on renal fibrosis and inflammation in animal
model or human studies. In unilateral ureter obstruction,
pentoxifylline effectively inhibits renal fibrosis by blocking
Smad3/4-activated transcription.16 Navarro et al. also
demonstrated that pentoxifylline abrogates the increase of
pro-inflammatory cytokines TNF-a, interleukin-1 (IL-1), and
IL-6 renal expression in diabetic nephropathy animal
model.36 Han et al. showed that pentoxifylline decreased
MCP-1 in animal DM model.19 Further, there was evidence
that pentoxifylline could attenuate renal functionFigure 2 Subgroup analysis of KaplaneMeier curve of the proport
and without pentoxiphylline. (A) Low proteinuria subgroup. There w
High proteinuria subgroup. Patients treated with a combination of
those treated with ACEI or ARB only. ACEI Z angiotensin-convertinprogression in a remnant kidney animal model.17 In
humans, pentoxifylline could suppress renal MCP-1 in pa-
tients with proteinuric primary glomerular disease22 and
urinary TNF-a and MCP-1 in CKD patients.27 Goicoechea
et al. found that pentoxifylline could decrease high-
sensitivity C-reactive protein, serum fibrinogen, and TNF-
a in CKD patients.21
Our study illustrated that patients with an older age
were associated with a slower trend of progression to ESRD,
especially those more than 65 years. This effect was more
prominent in the higher proteinuria subgroup. The finding
was compatible with other CKD cohorts showing that
elderly patients were associated with a less rapid GFR
decline in patients with eGFR levels< 45 mL/minute/
1.73 m2.37 Our analysis confirmed this view by demon-
strating fewer patients progressing to the need for RRT. Theion free from renal replacement therapy between groups with
as no difference in renal outcome between the two groups. (B)
pentoxifylline and ACEI or ARB had better renal outcome than
g enzyme inhibitor; ARB Z angiotensin II receptor blocker.
Table 4 Cox regression model for multivariate adjusted hazard ratio of developing ESRD requiring RRT by severity of
proteinuria.
Low proteinuria subgroup High proteinuria subgroup
HR (95% CI) p HR (95% CI) p
Pentoxifylline 1.955 (0.618e6.188) 0.254 0.602 (0.413e0.877) 0.008
Age
18e55 y 1.000 d 1.000 d
56e64 y 1.029 (0.229e4.627) 0.97 0.631 (0.395e1.006) 0.05
65e73 y 0.982 (0.232e4.160) 0.98 0.534 (0.307e0.929) 0.03
74e80 y 0.755 (0.153e3.722) 0.73 0.589 (0.335e1.037) 0.07
Sex (male) 1.819 (0.617e5.360) 0.28 1.903 (1.298e2.788) 0.001
eGFR (mL/minute/1.73 m2) 0.898 (0.843e0.956) 0.001 0.870 (0.845e0.895) <0.001
DM 0.903 (0.325e2.507) 0.84 0.940 (0.612e1.444) 0.78
BP  130/80 mmHg 1.674 (0.601e4.662) 0.32 0.869 (0.527e1.435) 0.58
Log UPCR (g/g) 0.847 (0.228e3.140) 0.80 11.17 (5.82e21.43) <0.001
Reference group age: 18e55 years.
BPZ blood pressure; CIZ confidence interval; DMZ diabetes mellitus; eGFRZ estimated glomerular filtration rate; ESRDZ end-stage
renal disease; HR Z hazard ratio; RRT Z renal replacement therapy; UPCR Z urine protein to creatinine ratio.
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competing with the outcome of ESRD in elderly patients,
and bias of the MDRD equation in the elderly patient group.
The younger patients might also have more severe renal
disease than the elderly patients.
Male sex is no doubt a predictor for CKD progression. In a
recently published study in Taiwan, men are at a 69% higher
risk of RRT initiation in Stages 3Be5 CKD patients. The
Stage 4e5 male CKD patients are especially vulnerable with
a 73e75% higher risk of RRT initiation.7 In our study, male
sex is not associated with a higher risk of ESRD requiring
RRT in the univariate analysis, but a strong association can
be observed in the multivariate analysis. The reason of this
finding is due to partial imbalance of patient selection. The
male participants of our cohort have lower baseline pro-
teinuria than female patients (mean: 0.980 vs. 1.430;
pZ 0.002). Therefore, the effect of male sex is masked by
the strong factor of proteinuria. After the correction of
proteinuria factor in the multivariate regression model, the
effect of sex is seen. Despite the imbalance of the baseline
proteinuria level between sexes, we still consider our
cohort cogent, because the relative risk of male sex in our
cohort is still similar to the other study in Taiwan.7
Our study had several limitations. First, this analysis is
retrospective in nature, and biases could exist affecting
the physician’s preference of prescribing pentoxifylline.
However, after comparing the baseline characteristics of
the two groups, no obvious difference was noted except
the status of DM. This difference may be attributed to the
previous studies stressing the efficacy of pentoxifylline in
diabetic nephropathy as mentioned earlier. Physicians
were therefore more likely to prescribe pentoxifylline for
these patients. Second, for patients with rapidly declining
renal function and low GFR, that is, mostly Stage 5 CKD
patients and rapidly progressing DM nephropathy patients,
physicians usually do not prescribe ACEI or ARB, and these
patients were excluded in this study. In this case, our
study population may not represent all advanced DM ne-
phropathy patients. Third, we assumed the medication
effect being equivalent regarding different classes of ACEIand ARB. The duration of ACEI or ARB use in both groups
showed no statistical difference. All patients received a
standard dosage of ACEI or ARB. Nearly no dosage change
was documented while prescribing them, and the per-
centage of medication cessation due to deterioration of
renal function or hyperkalemia was not different. There-
fore, we could cogently conclude that the use of ACEI or
ARB was equivalent in these two groups. Fourth, the
duration of pentoxifylline was not the same with different
follow-up period. The study was designed based on the
concept of intention to treat, which may weaken the ef-
fect of pentoxifylline. However, this study proved the
effectiveness of pentoxifylline in advanced CKD, which
may imply that the true effect of pentoxifylline may be
greater than that observed in the study. Besides, we also
did not evaluate the effect of different dosage of pen-
toxifylline. Because of the relatively small number of 3B
patients and significantly different renal function between
patients receiving different doses of pentoxifylline, it is
very difficult to compare the doseeeffect of pentoxifyl-
line. Besides, the drug concentration may be the same in
different CKD stage patients because the metabolism of
the drug was lower in late-stage patients although a lower
dose of pentoxifylline was prescribed.
In the multivariable Cox regression model, DM was not
associated with a higher risk of progression to ESRD
necessitating RRT. This result was incompatible with our
understanding that DM nephropathy declines faster than
nondiabetic nephropathy. We speculate the reason as the
following: first, the rate of renal function deterioration was
strongly correlated with urine protein loss in diabetic ne-
phropathy. Therefore, while adjusting the factors of DM
and UPCR together, the effect of DM would not be shown.
Second, patients with rapidly deteriorating renal function,
mainly DM nephropathy patients, were prone not to take
ACEI or ARB and were excluded from this study.
Despite the aforementioned limitations, this study pro-
vided evidence of the effectiveness of pentoxifylline
combined with ACEI or ARB. However, large-scale ran-
domized control trials are required to provide more
Add-on pentoxifylline protect kidney 225concrete evidence supporting the use pentoxifylline in CKD
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